Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Share-based Compensation (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Share-based Compensation data on record, last reported at $21.7 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 15.26% year-over-year to $21.7 million; the TTM value through Dec 2025 reached $91.0 million, up 31.18%, while the annual FY2025 figure was $91.0 million, 31.18% up from the prior year.
  • Share-based Compensation reached $21.7 million in Q4 2025 per CRNX's latest filing, down from $22.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $26.1 million in Q2 2025 and bottomed at $3.4 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $12.3 million, with a median of $10.6 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: skyrocketed 86.14% in 2024, then rose 15.26% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $5.2 million in 2021, then soared by 54.09% to $7.9 million in 2022, then surged by 46.16% to $11.6 million in 2023, then skyrocketed by 62.22% to $18.8 million in 2024, then increased by 15.26% to $21.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $21.7 million in Q4 2025, $22.7 million in Q3 2025, and $26.1 million in Q2 2025.